Literature DB >> 22403279

Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes.

Feng Zhou1, Hua Xin, Tao Liu, Guang-Yong Li, Zhe-Zhu Gao, Jing Liu, Wei-Ren Li, Wan-Shou Cui, Guang-Yi Bai, Nam Cheol Park, Zhong Cheng Xin.   

Abstract

Icariin and icariside II (ICA II), 2 active components isolated from herba epimedii, have a closely structural relationship. There is evidence that icariin may be useful in the treatment of erectile dysfunction (ED); however, the study on the therapeutic efficacy of ICA II on ED is currently scant. We investigated the effects of ICA II on improving erectile function of rats with streptozocin-induced diabetes. Fifty 8-week-old Sprague-Dawley rats were randomly distributed into normal control and diabetic groups. Diabetes was induced by a one-time intraperitoneal injection of streptozocin (60 mg/kg). Three days later, the diabetic rats were randomly divided into 4 groups including a saline-treated placebo arm and 3 ICA II-treated models (1, 5, and 10 mg/kg/d). After 3 months, penile hemodynamics was measured by cavernous nerve electrostimulation (CNE) with real time intracorporal pressure assessment. Penises were harvested with subsequent histological examination (picrosirius red stain, Hart elastin stain, and immunohistochemical stain) and Western blots to explore the expression of the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) and transforming growth factor β1 (TGFβ1)/Smad2 signaling pathways. Diabetes significantly attenuated erectile responses to CNE. Diabetic rats had decreased corpus cavernosum smooth muscle/collagen ratio and endothelial cell content relative to the control group. The ratio of collagen I to III was significantly lower in the corpora of diabetic rats; furthermore, cavernous elastic fibers were fragmented in the diabetic animals. Neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase, and vascular endothelial growth factor were expressed at lower levels in the diabetic group; ICA II-treated diabetic rats had higher expression in the penis relative to placebo-treated diabetic animals. Both the TGFβ1/Smad2/connective tissue growth factor (CTGF) signaling pathway and apoptosis were down-regulated in the penis from ICA II-treated rats. ICA II treatment attenuates diabetes-related impairment of penile hemodynamics, likely by increasing smooth muscle, endothelial function, and nNOS expression. ICA II could alter corpus cavernosum fibrous-muscular pathological structure in diabetic rats, which could be regulated by the TGFβ1/Smad2/CTGF and NO-cGMP signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403279     DOI: 10.2164/jandrol.111.015172

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  19 in total

1.  Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model.

Authors:  Xuefeng Qiu; Guiting Lin; Zhongcheng Xin; Ludovic Ferretti; Haiyang Zhang; Tom F Lue; Ching-Shwun Lin
Journal:  J Sex Med       Date:  2012-12-17       Impact factor: 3.802

2.  Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience.

Authors:  Wei-Dong Song; Yi-Ming Yuan; Wan-Shou Cui; Alex K Wu; Yi-Chen Zhu; Jing Liu; Lin Wang; Guang-Yi Bai; Jing Peng; Zhi-Chao Zhang; Bing Gao; Ying-Lu Guo; Tom F Lue; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2013-07-22       Impact factor: 3.285

3.  Efficacy and safety of novel low-intensity pulsed ultrasound (LIPUS) in treating mild to moderate erectile dysfunction: a multicenter, randomized, double-blind, sham-controlled clinical study.

Authors:  Wanshou Cui; Huixi Li; Ruili Guan; Meng Li; Bicheng Yang; Zhanwei Xu; Maofan Lin; Long Tian; Xiaodong Zhang; Bao Li; Weiguang Liu; Zhilong Dong; Zhiping Wang; Tao Zheng; Weixing Zhang; Guiting Lin; Yinglu Guo; Zhongcheng Xin
Journal:  Transl Androl Urol       Date:  2019-08

4.  Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats.

Authors:  Wenjie Tian; Hongen Lei; Ruili Guan; Yongde Xu; Huixi Li; Lin Wang; Bicheng Yang; Zhezhu Gao; Zhongcheng Xin
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162

Review 5.  Low-intensity shock wave therapy and its application to erectile dysfunction.

Authors:  Hongen Lei; Jing Liu; Huixi Li; Lin Wang; Yongde Xu; Wenjie Tian; Guiting Lin; Zhongcheng Xin
Journal:  World J Mens Health       Date:  2013-12-24       Impact factor: 5.400

6.  Effects of Icariside II on corpus cavernosum and major pelvic ganglion neuropathy in streptozotocin-induced diabetic rats.

Authors:  Guang-Yi Bai; Feng Zhou; Yu Hui; Yong-De Xu; Hong-En Lei; Jin-Xian Pu; Zhong-Cheng Xin
Journal:  Int J Mol Sci       Date:  2014-12-15       Impact factor: 5.923

7.  Optimized Biotransformation of Icariin into Icariside II by β-Glucosidase from Trichoderma viride Using Central Composite Design Method.

Authors:  Tao Cheng; Jun Yang; Tong Zhang; Yi-Shun Yang; Yue Ding
Journal:  Biomed Res Int       Date:  2016-02-14       Impact factor: 3.411

8.  Antioxidant icariside II combined with insulin restores erectile function in streptozotocin-induced type 1 diabetic rats.

Authors:  Lin Wang; Yongde Xu; Huixi Li; Hongen Lei; Ruili Guan; Zhezhu Gao; Zhongcheng Xin
Journal:  J Cell Mol Med       Date:  2015-03-17       Impact factor: 5.310

9.  Effects of Next-Generation Low-Energy Extracorporeal Shockwave Therapy on Erectile Dysfunction in an Animal Model of Diabetes.

Authors:  Hyun Cheol Jeong; Seung Hwan Jeon; Zhu Guan Qun; Kang Sup Kim; Sae Woong Choi; Fahad Bashraheel; Woong Jin Bae; Su Jin Kim; Hyuk Jin Cho; U Syn Ha; Sung Hoo Hong; Ji Youl Lee; Du Geon Moon; Sae Woong Kim
Journal:  World J Mens Health       Date:  2017-11-20       Impact factor: 5.400

10.  Prophylactic protective effects and its potential mechanisms of IcarisideII on streptozotocin induced spermatogenic dysfunction.

Authors:  Yongde Xu; Hongen Lei; Ruili Guan; Zhezhu Gao; Huixi Li; Lin Wang; Yu Hui; Feng Zhou; Zhongcheng Xin
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.